NasdaqCM - Nasdaq Real Time Price USD

Nuvectis Pharma, Inc. (NVCT)

8.85

-0.12

(-1.34%)

At close: June 6 at 4:00:00 PM EDT

8.85

0.00

(0.00%)

After hours: June 6 at 4:04:06 PM EDT

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Inves

GlobeNewswire 22 days ago

NVCT
-1.34%
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 108.8% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 29 days ago

NVCT
-1.34%
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

NVCT
-1.34%
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or th

GlobeNewswire last month

NVCT
-1.34%
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nuvectis Pharma Inc (NASDAQ:NVCT) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]

Insider Monkey last month

NVCT
-1.34%
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC For

GlobeNewswire last month

NVCT
-1.34%
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2025 American Association for Cancer Research Meeting (2025 AACR), taking place from April 25th to April 30th in Chicago, IL. Presentation

GlobeNewswire 2 months ago

NVCT
-1.34%
Nuvectis Pharma to Participate in the 37th Annual Roth Conference

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch

GlobeNewswire 2 months ago

NVCT
-1.34%
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

NEW YORK, March 05, 2025--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to decre

Business Wire 3 months ago

NVCT
-1.34%
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University)Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a new publication from the laboratory of Prof. Ruth Keri, (Cleveland Clinic, Cleve

GlobeNewswire 3 months ago

NVCT
-1.34%
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

NEW YORK, February 27, 2025--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need.

Business Wire 3 months ago

NVCT
-1.34%
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is underway. Phase 1b program expected to begin in mid-2025Follow-on offering completed in February 2025 extends cash runway into 2027 FORT LEE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis

GlobeNewswire 3 months ago

NVCT
-1.34%
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter’s option to purchase 405,000 additional shares. The common stock

GlobeNewswire 3 months ago

NVCT
-1.34%
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also

GlobeNewswire 3 months ago

NVCT
-1.34%
Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day optio

GlobeNewswire 3 months ago

NVCT
-1.34%
Favourable Signals For Nuvectis Pharma: Numerous Insiders Acquired Stock

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 4 months ago

NVCT
-1.34%
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently

Key Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth 57% of the...

Simply Wall St. 4 months ago

NVCT
-1.34%
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators

GlobeNewswire 5 months ago

NVCT
-1.34%
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Nuvectis Pharma (NVCT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 6 months ago

NVCT
-1.34%
Nuvectis Pharma reports data from Phase 1b study of NXP800

Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration and NXP800 was granted Orphan Drug Desig

TipRanks 6 months ago

NVCT
-1.34%

Performance Overview

Return	NVCT	S&P 500 (^GSPC)
YTD	+63.59%	+2.02%
1-Year	+35.53%	+12.09%
3-Year	-28.34%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Favourable Signals For Nuvectis Pharma: Numerous Insiders Acquired Stock

Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Nuvectis Pharma reports data from Phase 1b study of NXP800

Performance Overview